<DOC>
	<DOC>NCT01188759</DOC>
	<brief_summary>This study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspergillosis.</brief_summary>
	<brief_title>Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Neuroaspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Diagnosis of proven, probable, or possible invasive aspergillosis. Hematologic malignancy or allogeneic hematopoetic stem cell transplant. Sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis. Chronic invasive aspergillosis. Receipt of antifungal treatment for more than 96 hours. Severe liver dysfunction.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Aspergillosis</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Voriconazole</keyword>
	<keyword>Anidulafungin</keyword>
</DOC>